LDH as a Prognostic and Monitoring Marker in Non‑Hodgkin Lymphoma

Prognostic Thresholds

• An LDH level of 550 U/L is below the critical cutoff of 1.5 × the upper limit of normal (generally <600–750 U/L), which is the threshold used in major NHL prognostic scoring systems. 1
• In the International Prognostic Index (IPI), an elevated LDH (>1 × ULN) counts as one adverse factor among the five risk components. 2

Risk Stratification

• For patients whose LDH is <1.5 × ULN (good‑prognosis NHL), the 5‑year progression‑free survival is approximately 90 % and the 5‑year overall survival is about 96 %. 1
• The LENT score for malignant pleural effusions assigns 0 points when LDH is <1500 IU/L, indicating a lower‑risk category. 3
• Individuals with LDH between the normal range and 2 × ULN are typically classified as low‑to‑intermediate risk, with a median survival exceeding 18 years in the modern rituximab‑based treatment era. 2

Interpretation with Other IPI Components

• The prognostic impact of an LDH of 550 U/L must be considered together with the other IPI factors: age > 60 years, Ann Arbor stage III–IV, ECOG performance status ≥ 2, and more than one extranodal disease site. 2

Monitoring Post‑Treatment

• Serum LDH should be measured at 3, 6, 12, and 24 months after therapy; normalization suggests complete remission, whereas persistent elevation points to residual disease or relapse. 4

Histology‑Specific Implications

• In follicular lymphoma, LDH is incorporated into both the FLIPI and FLIPI2 indices; elevated LDH denotes higher‑risk disease and warrants more intensive monitoring. 2

Serum LDH in Non‑Hodgkin Lymphoma: Role in Diagnosis, Staging, and Treatment

Diagnostic Role of LD H

• The National Comprehensive Cancer Network (NCCN) guidelines state that serum LD H is incorporated into the NHL work‑up solely as a prognostic and risk‑stratification marker; a normal LD H level does not exclude the diagnosis of NHL and should not be used to rule out disease. 5

• According to NCCN (2011), definitive diagnosis of NHL requires tissue biopsy with immunophenotyping; serum LD H is not a diagnostic criterion. 5

Prognostic and Staging Use of LD H

• NCCN recommends measuring serum LD H as an essential component of staging and prognostic assessment for NHL, because elevated LD H correlates with higher tumor burden and aggressive disease, but it is not required for establishing the diagnosis. 6

• The guidelines advise that clinicians should not dismiss the possibility of NHL when LD H is normal, especially in early‑stage (I‑II) or low‑grade histologies, which frequently present with normal LD H levels. [5][6]

Pediatric Risk Stratification and Treatment Intensity

• In pediatric aggressive B‑cell lymphomas, the NCCN (2020) defines high‑risk disease (Group B) by LD H > 2 × the upper limit of normal; patients with stage III disease but LD H ≤ 2 × ULN are classified as low‑risk (Group A). 7

• NCCN pediatric protocols use LD H thresholds to assign therapy intensity: different LD H cut‑offs determine assignment to treatment groups A, B, or C, guiding the aggressiveness of chemotherapy regimens. 7

Role of Lactate Dehydrogenase (LDH) in the Diagnosis, Staging, and Prognosis of Non‑Hodgkin Lymphoma

Diagnostic Approach

• Clinical suspicion of NHL should be based on presenting features such as lymphadenopathy, B‑symptoms, cytopenias, or organomegaly, and should be pursued irrespective of the serum LDH level. The NCCN clinical practice guideline emphasizes that a normal LDH does not rule out disease. 8

Staging Work‑up

• Serum LDH measurement is incorporated into the standard staging work‑up (alongside CBC, comprehensive metabolic panel, imaging, and bone‑marrow biopsy) to evaluate tumor burden and provide prognostic information. This recommendation is supported by both the NCCN guideline and contemporary oncology literature. 8, 9

Risk Stratification

• After histologic confirmation, LDH is used for risk stratification: the International Prognostic Index (IPI) for aggressive NHL and the Follicular Lymphoma International Prognostic Index (FLIPI/FLIPI2) for follicular lymphoma incorporate LDH as a key adverse factor. Normal LDH does not exclude high‑risk disease, but elevated LDH contributes to a higher risk score. 9

Monitoring Post‑Therapy (Evidence Not Cited)

• [No cited source provided for post‑treatment LDH monitoring; therefore omitted per instructions.]